Regeneron, Rival End Patent Fight Over Eye Med Biosimilar
By Adam Lidgett · October 21, 2025, 6:20 PM EDT
Regeneron and a South Korea-based rival it had accused of infringing several patents covering the U.S. biotech company's top eye medication Eylea have agreed to a settlement to put an end...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login